Publication | Open Access
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
128
Citations
26
References
2022
Year
During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19-related hospitalization among children 5 to 11 years of age.
| Year | Citations | |
|---|---|---|
Page 1
Page 1